SpeedPe

SpeedPe

SpeedPe operates as the investment office for Sudhir Valia, a chartered accountant who spent decades as the financial architect behind Sun Pharmaceutical Industries — India's largest pharmaceutical company by market capitalization. The firm deploys Valia's personal capital into early-stage and growth-stage companies, functioning as a single family office rather than a pooled venture fund. It has backed more than 80 startups across India's technology ecosystem, with a particular focus on founders building in fintech, healthcare, enterprise software, and consumer internet. The portfolio spans a deliberately wide aperture. SpeedPe has invested in companies including fintech infrastructure provider M2P Fintech, agritech platform DeHaat, and healthtech startup Lybrate — demonstrating a pattern of backing asset-light platforms that digitize India's large informal sectors. The firm participates in seed through Series B rounds, typically writing checks alongside established venture firms like Sequoia Capital India and Accel. It does not operate a fund-of-funds model; capital is deployed directly into portfolio companies via equity and convertible instruments. The geographic focus is almost exclusively India, with occasional co-investment in companies serving cross-border corridors in Southeast Asia and the Middle East. Valia runs SpeedPe alongside his role as a non-executive director at Sun Pharma and his involvement with other family ventures including Sun Foundation, the family's philanthropic arm. The office maintains a lean team in Mumbai and does not publicly disclose headcount or assets under management. A known operational move: the firm has recently increased its check size into growth-stage companies, participating in larger Series B and C rounds after years of concentrating on seed-stage exposure (per Entrackr, 2023). SpeedPe's structural difference lies in its single-LP architecture embedded inside a first-generation fortune still actively managed by its creator. Unlike institutionalized family offices with investment committees and CIOs, Valia makes allocation decisions directly — a model that collapses diligence-to-term-sheet timelines. For founders, access to the Valia network, including informal connections into the pharmaceutical distribution and regulatory landscape, operates as a parallel value proposition beyond the check itself.